- Healthcare Huddle
- Posts
- Fast-Track Approval: Balancing Speed and Safety in Drug Approvals
Fast-Track Approval: Balancing Speed and Safety in Drug Approvals
Huddle+ | Huddle #Trends
Jared Dashevsky, MD
January 07, 2023 • Estimated Reading Time: 1 minute
Huddle #Trends are monthly reports dissecting key healthcare trends that impact patients, physicians, and the system. Exclusive to Huddle+ members.
The FDA’s Fast Track approval program, designed to speed drug development for life-threatening conditions, has faced increased scrutiny over the years. I’ve mainly used Biogen’s controversial Alzheimer’s drug Aduhelm to shed light on the accelerated approval problems. However, the problems run deeper than Aduhelm.
In this article, I’ll highlight the FDA’s Fast Track approval program, dive into its fundamental problems, and discuss solutions to improve the much-needed program.
Subscribe to Huddle+ to read the rest.
Become a paying subscriber of Huddle+ to get access to this post and other subscriber-only content.
Already a paying subscriber? Sign In.
A subscription gets you:
- • Traditional Sunday Healthcare Huddle newsletter and...
- • Exclusive Content: Weekly Inefficiency Insights and Monthly Huddle #Trends newsletters
- • Huddle University: Courses on essential healthcare topics
- • The Huddle Community: Connect with a network of healthcare professionals, share insights, and stay ahead in the industry
- • Discount for physicians, trainees, providers, students, employers. Email [email protected]